To secure biotech seed funding, follow a sequence, not a wish list: get your science and team ready, exhaust nondilutive capital first, map your FDA pathway before you pitch, budget to milestones instead of months, pick the right instrument, then run outreach through warm channels only. Investors expect you to have already touched SBIR, sketched a regulatory route with FDA in mind, and, if your science overlaps with human health research priorities, know whether NIH funding mechanisms apply to your program.
Here's what to do this week:
- Audit your founding team for gaps in regulatory, clinical, or CMC experience.
- Confirm IP status: filed, provisional, or still unprotected.
- Start an SBIR/STTR application if your science qualifies for nondilutive funding.
- Draft a 12 to 18 month milestone budget tied to concrete regulatory events.
- List 15 to 20 investors whose portfolios match your indication and stage.
- Sketch your regulatory pathway (505(b)(2), traditional NDA, or biologics route).
- Build the skeleton of a data room, even if half the folders are empty.
- Identify one advisor who can make a warm introduction to a credible lead investor.
Key Takeaways
Securing biotech seed funding requires sequencing nondilutive capital, regulatory clarity, and milestone-based budgeting before approaching equity investors at all.
| Point | Details |
|---|---|
| Start nondilutive | Pursue SBIR/STTR grants first; a Phase I award can provide roughly $250,000 without diluting equity. |
| Map regulatory milestones | Tie funding tranches to IND acceptance, first patient dosed, and Phase I completion, not calendar dates. |
| Size the raise correctly | Budget 12 to 18 months of runway toward one undeniable milestone, not three partial ones. |
| Avoid governance chaos | Secure a credible lead investor before finalizing board seats to prevent fragmented, slow-moving cap tables. |
| Compress operational timelines | Partners like Haiphai help reclaim months on regulatory drafting and site activation ahead of key fundraising milestones. |
This article is general information, not a substitute for advice from a qualified financial advisor. Consult a qualified financial professional about your own circumstances before acting on anything here.
Table of Contents
- Step 0: Prepare Your Business Case, Team, and Data Room
- Where Should You Look for Pre-Seed and Seed Capital?
- How Much Should You Raise, and How Long Should It Last?
- Which Financing Instrument Fits Your Round?
- How Do You Find and Pitch the Right Investors?
- Why Your Regulatory Pathway Is a Fundraising Asset
- What Should You Watch for When Negotiating Terms?
- What Happens After the Round Closes?
- How Operational Partners Shorten the Path to Funding
- What Experienced Founders Get Wrong Early
- How Haiphai Helps You Get Fundraise Ready Faster
- Sources
- FAQ
Step 0: Prepare Your Business Case, Team, and Data Room
Nobody writes a check before your fundamentals are in order, and biotech fundamentals are stricter than most first-time founders expect. Skipping this step is the single fastest way to burn three months on meetings that go nowhere.
Team composition matters more than most founders assume. A CEO with no regulatory or clinical trial experience raises red flags immediately unless they've deliberately paired with a CMO who has run an IND submission before. Board composition matters too: investors want at least one seat held by someone who has actually taken a drug or device through FDA review, not just a friendly advisor with a nice title.
IP needs to be more than a provisional filing. You need a clear distinction between composition-of-matter claims and method-of-use claims, and a freedom-to-operate summary that names the two or three most relevant blocking patents in your space, if any exist. A one-page FTO memo written by patent counsel carries more weight in diligence than a 40-slide IP appendix.
Milestones should be regulatory events, not calendar dates. "We'll be done with preclinical work by Q3" means nothing to an investor. "We'll complete IND-enabling toxicology and file with FDA by month 14" means everything, because it maps directly to value creation.
Your data room table of contents should include:
- Investment memo and executive summary
- Executive and advisor bios with relevant regulatory or clinical track records
- Patent summary and freedom-to-operate memo
- CMC (chemistry, manufacturing, and controls) plan
- Preclinical data package
- Regulatory strategy memo
- Financial model with use-of-proceeds breakdown
- Milestone schedule tied to funding tranches
Biotech due diligence differs sharply from software diligence. Investors want defensible IP, CMC readiness, and regulatory clarity, not monthly recurring revenue or user growth charts. Build the data room with that in mind from day one, and lean on resources like a due diligence checklist for investment executives so you can see the questions coming before they're asked.
Where Should You Look for Pre-Seed and Seed Capital?
Sequence matters here as much as selection. Chase capital in the wrong order and you'll either dilute too early or waste months courting investors who were never going to write a check at your stage.
- Nondilutive grants first. An SBIR Phase I award can provide around $250,000 for proof-of-concept work, letting you hit valuation-increasing milestones before giving up equity. STTR grants work similarly if you're partnering with a university lab.
- Disease foundations and venture philanthropy. Groups tied to specific conditions often fund translational research years before a typical VC would touch it, and their money rarely comes with board seats attached.
- Mission-aligned family offices. These have become a genuine third pillar in early biotech financing, not just VCs and grants but family offices bridging the valley of death between academic proof-of-concept and institutional-grade data.
- Specialized angel syndicates and biotech accelerators. Life-science angel deals make up a smaller slice of total deal count but a larger share of capital deployed, meaning life-science angels tend to write bigger checks than angels in other sectors. Programs modeled on Y Combinator's cohort structure, along with biotech-specific accelerators, can also open doors here.
- Seed VCs last. Most institutional seed funds want at least a hint of clinical or regulatory traction before committing.
Crowdfunding and Reg CF platforms can work for consumer diagnostics or wellness-adjacent products, but institutional biotech VCs almost always require a clinical or regulatory inflection point before engaging.
How Much Should You Raise, and How Long Should It Last?
Most pre-seed and seed biotech rounds should fund 12 to 18 months of runway, ending at a milestone dramatic enough to justify a valuation step-up. Raising less just delays the inevitable; raising far more than that dilutes you before you've proven anything.
Build your number from the milestone backward:
- List every IND-enabling activity: toxicology studies, CMC development, formulation work.
- Price out regulatory consulting hours for your FDA pre-submission meeting.
- Add preclinical study costs, including any contract research organization fees.
- Layer in operational overhead: salaries, lab space, insurance, legal.
- Add a 15 to 20% buffer, because biotech timelines slip more often than they compress.
The regulatory pathway you choose changes this math substantially. A 505(b)(2) pathway can require tens of millions to reach an NDA, while a full novel drug program often runs past $100 million before approval, so know which road you're on before you set your first-round target.
Pro Tip: Size your raise to hit one undeniable milestone, not three ambitious ones. A single clean data point that de-risks the science is worth more to your next round than three half-finished experiments.
Which Financing Instrument Fits Your Round?
The instrument you choose signals maturity to investors as much as it structures the deal itself. Get this wrong and you either give away too much control too early or scare off a lead who wants clean terms.
SAFEs and convertible notes work well for true pre-seed rounds where you're selling option value on unproven science. They're fast, cheap to paper, and avoid pinning down a valuation before you have data to defend one. Priced rounds make more sense once you have an institutional lead willing to set terms, typically at the tail end of seed when you're heading into IND-enabling work with real preclinical results in hand.
Model your dilution before you negotiate, not after. Run your own numbers with actual terms. Carta has become the standard tool most biotech founders use to model these scenarios and manage the resulting cap table without spreadsheet errors piling up.
Governance basics to nail down early:
- Identify your lead investor before you finalize board composition.
- Cap board seats at a number that keeps decision-making fast, not politically gridlocked.
- Include standard protective provisions without over-conceding on future financing control.
- Avoid party rounds where five funds each own a sliver and nobody feels responsible for governance.
Team composition and cap table cleanliness are linked more than founders realize. A messy cap table often traces back to weak team decisions early made under time pressure during a rushed raise.
How Do You Find and Pitch the Right Investors?
Find your lead before you build your full investor list. A credible lead who can validate the science publicly does more to fill out your round than fifty cold emails ever will, because other investors calibrate their interest off who's already committed.
Warm introductions convert at dramatically higher rates than cold outreach in biotech, where scientific credibility travels through personal networks. Ask your scientific advisors, former colleagues, and even your patent attorney for introductions. A repeatable cadence looks like this: intro email from a mutual contact, 30-minute scientific overview call, deeper technical diligence session, then a handoff to the investor's internal team for financial and legal review.
Your pitch deck needs biotech-specific components that a generic startup template won't cover:
- Mechanism of action explained in one clear slide, not three dense ones.
- Preclinical data highlights, with the strongest single result front and center.
- Regulatory pathway summary showing you understand which route you're on and why.
- CMC plan overview, even at a high level, showing manufacturing feasibility.
- Milestone roadmap tied explicitly to the funding tranches you're requesting.
- Clear use of funds broken down by category, not a vague "R&D and operations" line.
Diligence timelines have stretched to six to nine months in many cases, with investors now probing regulatory clarity and leadership resilience far more deeply than they did a few years ago. Build your outreach timeline assuming that pace, not a 60-day sprint. Understanding how the venture capital evaluation process actually works before your first meeting saves you from misreading slow responses as rejection.
Why Your Regulatory Pathway Is a Fundraising Asset
A vague regulatory plan reads as risk to investors. A specific one reads as a reason to write a bigger check. Founders who design regulatory and reimbursement strategy before approaching investors consistently raise on better terms than those who treat it as a Series A problem.
Map your capital tranches directly to regulatory inflection points rather than arbitrary dates:
- Tranche one: fund the work needed to reach IND acceptance.
- Tranche two: fund activities through first patient dosed.
- Tranche three: fund completion of Phase I data readout.
The FDA's own development and approval process documentation is worth reading closely, including the administrative clocks like the 30-day IND review window, since these dates anchor your milestone schedule in something verifiable rather than optimistic guessing.
Don't skip reimbursement thinking just because you're years from commercial launch. Investors increasingly ask how payers will evaluate your eventual product and what evidence you'll need to generate along the way. A one-paragraph summary of your expected commercial pathway, including likely payer categories and comparable reimbursement precedents, shows you're thinking past approval.
Pro Tip: Put your regulatory milestone map on one slide in your deck. Investors remember the founder who could explain their FDA pathway in thirty seconds far better than the one who buried it in an appendix.
What Should You Watch for When Negotiating Terms?
Term sheets in biotech seed rounds hinge on a handful of decisions that matter far more than the headline valuation number. Prioritize these:
- Valuation mechanics: understand pre versus post-money math before you negotiate anything else.
- Tranche triggers: tie milestone-based capital releases to specific, unambiguous regulatory events.
- Liquidation preference: push back hard on anything beyond a standard 1x non-participating preference.
- Board seats: keep the count small enough to move fast.
- Protective provisions: know exactly which decisions require investor consent before you sign.
Watch for red flags that hurt you later even if they feel harmless now: party rounds with no clear lead, a cap table fragmented across a dozen small checks, or an investor with no domain experience who will slow down every technical decision with basic questions.
A tight closing checklist speeds up time-to-cash: finalize legal documents, get a signed commitment letter from your lead, confirm wire instructions early, and settle governance mechanics like board meeting cadence before the money lands, not after.
What Happens After the Round Closes?
Capital stewardship starts the day the wire hits your account. Set a reporting cadence, monthly or quarterly, covering scientific progress, operational milestones, and burn against plan. Investors who feel informed stay patient; investors left guessing start asking uncomfortable questions.
Track burn against your milestone budget weekly, not monthly, so a slipping timeline shows up before it becomes a crisis. If a milestone runs late, raise a bridge ahead of running out of cash rather than after, using tools like a bridge financing framework built specifically for early biotech runway gaps.
- Report science, operations, and financials on a fixed schedule.
- Track weekly burn against your milestone budget, not just monthly totals.
- Use early wins, a grant award, IND acceptance, first patient dosed, to reprice your next raise upward.
- Start Series A conversations before you desperately need the money.
Early proof points do more than validate the science. They let you approach Series A leads from a position of leverage instead of scarcity.
How Operational Partners Shorten the Path to Funding
Founders often underestimate how much time regulatory drafting and clinical site activation eat up, time that should be spent fundraising or advancing science instead. An embedded operational partner can reclaim months on these bottlenecks, which directly affects your fundability since a faster IND filing or an earlier first-in-human dose changes what you can credibly promise investors.
When evaluating any operational partner, ask pointed questions:
- What outcome-based KPIs do they track, not just activity metrics?
- Can they show how their process integrates with your existing team rather than replacing institutional knowledge?
- What's their governance model for handoffs and accountability?
- Do they tailor workflows to your program, or apply a generic template regardless of your science?
Founders who've compressed timelines this way typically report a better-prepared data room heading into diligence, a faster regulatory filing than their original internal timeline projected, and the ability to point to a concrete near-term milestone during investor conversations instead of a vague "sometime next year."
What Experienced Founders Get Wrong Early
Most first-time biotech founders overinvest in the pitch deck and underinvest in the team and regulatory map that make the deck credible. The founders who raise cleanly are the ones who fixed their board composition and sketched their FDA pathway before they scheduled a single investor meeting. Party rounds feel like validation in the moment; six months later they're the reason nobody can make a fast decision.
Hire full-time for what you'll need for years. Bring in a partner for what you need to move fast right now.
How Haiphai Helps You Get Fundraise Ready Faster
Every step in this playbook assumes you have the operational bandwidth to execute on regulatory drafting, data room prep, and site activation while also running a fundraise, and most founding teams simply don't. Haiphai steps in as an embedded operational partner, mapping your bottlenecks backward from your funding milestones so the regulatory memo, CMC plan, and preclinical package in your data room are ready before your first term sheet conversation, not scrambled together after.
A diagnostic engagement typically starts with a review of your current timeline, team structure, and regulatory plan, then identifies where AI-enabled workflows can compress months of drafting and activation work. Founders walk away with a clear picture of what's fixable and what it would take to fix it. Deliverables from an initial diagnostic generally include:
- A bottleneck map across your regulatory and clinical operations
- A milestone timeline showing where time can realistically be reclaimed
- A prioritized action list tied directly to your next fundraising milestone
Bring your current milestone budget and data room outline to the conversation. If you're preparing for a raise and want a clearer sense of where your timeline can tighten, request a diagnostic with Haiphai to see what's possible before you finalize your fundraising calendar.
Sources
- Sbir
- Is your startup prepared to navigate the intersection of regulation and reimbursement?
- Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
- FDA — Development & approval process (drugs)
- Biotech Startup Fundraising FDA Pathway: Complete | AIN
- 2024 biotech asset valuation methods — practitioners guide (Harvard M-RCBG)
FAQ
How much should a biotech startup raise in a seed round?
Most seed rounds target 12 to 18 months of runway, sized to reach one clear regulatory or preclinical milestone rather than spreading thin across several.
Should biotech founders use a SAFE or a priced round?
SAFEs and convertible notes fit true pre-seed rounds without proven data, while priced rounds suit later seed stages once an institutional lead is ready to set valuation terms.
What makes a biotech pitch deck different from a typical startup deck?
A biotech deck needs a mechanism-of-action slide, preclinical data highlights, a regulatory pathway summary, a CMC overview, and a milestone roadmap tied to specific funding tranches.
How can founders shorten the path to their first fundable milestone?
Embedding an operational partner like Haiphai to handle regulatory drafting and clinical site activation can compress timelines that would otherwise consume months of internal bandwidth.
Do investors expect a regulatory pathway before seed funding?
Yes. Investors increasingly evaluate startups on the clarity of their FDA pathway and reimbursement thinking, not just the strength of the underlying science.